Prediction Case File
YouTubeEvaluation Complete

Pfizer Stock Prediction and Forecast [PFE]

1 extracted signal · 1 resolved · 0 still active

StockInvest.us profile imageStockInvest.us02 Oct 2025, 04:04 UTC
Video preview for Pfizer Stock Prediction and Forecast [PFE]
Signals
1
Eligible signals in this source
Open
0
Still being tracked
Resolved
1
Evaluable outcomes
Successful
1
Canonical correct result
Failed
0
Canonical failed result
Resolved success
100%
Open and excluded signals omitted
Source overview

AI-generated source summary

The analysis focuses on Pfizer (PFE) stock, noting it holds several positive signals but doesn't qualify as a buy candidate, suggesting a hold/accumulate strategy. The predicted opening price for the next trading day is $0.467 lower, around $26.74. Support lies at $24.59 to $24.72. A breakdown below these levels indicates a sell signal. The trend suggests a potential decrease of 2.31% over the next three months, with a possible return ranging from -17.87% to -8.02%. The analysis advises close monitoring, pointing to a divergence between volume and price. Technical indicators suggest further upside. Fibonacci theory suggests the resistance level at $27.69 as possible resistance.

AI-generated summary based on the source content.

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

  4. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  5. Market predictions extracted

    1 eligible signal linked to this case.

  6. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

Extracted intelligence

Signals in this source

Continue the evidence trail
Analyst history

StockInvest.us

Tracked signals
1521
Historical success
43.3%
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.